249 related articles for article (PubMed ID: 24359492)
1. Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients.
Borrás-Blasco J; Gracia-Pérez A; Rosique-Robles JD; Casterá ME; Abad FJ
Expert Opin Biol Ther; 2014 Feb; 14(2):145-50. PubMed ID: 24359492
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of etanercept 50 mg once weekly in Japanese patients with rheumatoid arthritis and comparison with 25 mg etanercept twice weekly.
Mochizuki T; Momohara S; Yano K; Shirahata T; Ikari K
Mod Rheumatol; 2013 Sep; 23(5):994-1000. PubMed ID: 23138447
[TBL] [Abstract][Full Text] [Related]
3. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
4. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
5. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
[TBL] [Abstract][Full Text] [Related]
6. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
7. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
[TBL] [Abstract][Full Text] [Related]
8. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.
van Vollenhoven RF; Østergaard M; Leirisalo-Repo M; Uhlig T; Jansson M; Larsson E; Brock F; Franck-Larsson K
Ann Rheum Dis; 2016 Jan; 75(1):52-8. PubMed ID: 25873634
[TBL] [Abstract][Full Text] [Related]
9. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose.
Raffeiner B; Botsios C; Ometto F; Bernardi L; Stramare R; Todesco S; Sfriso P; Punzi L
Clin Exp Rheumatol; 2015; 33(1):63-8. PubMed ID: 25535985
[TBL] [Abstract][Full Text] [Related]
10. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions.
Inciarte-Mundo J; Hernández MV; Rosario V; Ruiz-Esquide V; Cabrera-Villalba S; Ramírez J; Cañete JD; Sanmartí R
Reumatol Clin; 2014; 10(1):10-6. PubMed ID: 23876791
[TBL] [Abstract][Full Text] [Related]
11. Treating to target with etanercept in rheumatoid arthritis: cost-effectiveness of dose reductions when remission is achieved.
Kobelt G
Value Health; 2014 Jul; 17(5):537-44. PubMed ID: 25128046
[TBL] [Abstract][Full Text] [Related]
12. Educational session as a tool to increase patient satisfaction of switching etanercept from the prefilled syringe to the autoinjection pen.
Borrás-Blasco J; Gracia-Pérez A; Casterá MD; Rosique-Robles JD; Abad J
Expert Opin Biol Ther; 2013 Aug; 13(8):1103-8. PubMed ID: 23675687
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
14. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.
Boonen A; van der Heijde D; Severens JL; Boendermaker A; Landewé R; Braun J; Brandt J; Sieper J; van der Linden S
Ann Rheum Dis; 2006 Feb; 65(2):201-8. PubMed ID: 16014677
[TBL] [Abstract][Full Text] [Related]
15. Impact of a Patient Support Program on Patient Adherence to Adalimumab and Direct Medical Costs in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Rubin DT; Mittal M; Davis M; Johnson S; Chao J; Skup M
J Manag Care Spec Pharm; 2017 Aug; 23(8):859-867. PubMed ID: 28737994
[TBL] [Abstract][Full Text] [Related]
16. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.
Moreland LW; Cohen SB; Baumgartner SW; Tindall EA; Bulpitt K; Martin R; Weinblatt M; Taborn J; Weaver A; Burge DJ; Schiff MH
J Rheumatol; 2001 Jun; 28(6):1238-44. PubMed ID: 11409115
[TBL] [Abstract][Full Text] [Related]
17. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
Wu N; Lee YC; Shah N; Harrison DJ
Clin Ther; 2014 Aug; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
[TBL] [Abstract][Full Text] [Related]
18. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany.
Huscher D; Merkesdal S; Thiele K; Zeidler H; Schneider M; Zink A;
Ann Rheum Dis; 2006 Sep; 65(9):1175-83. PubMed ID: 16540552
[TBL] [Abstract][Full Text] [Related]
19. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
20. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
Paccou J; Baclé-Boutry MA; Solau-Gervais E; Bele-Philippe P; Flipo RM
J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
